ESMO 2022 | Perioperative treatment strategies for high-risk bladder cancer

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses the latest data on the management of high-risk muscle-invasive bladder cancer. Dr Bellmunt first discusses ongoing Phase III trials in the neoadjuvant space which are investigating the use of immunotherapy either alone or in combination with chemotherapy. Dr Bellmunt then discusses adjuvant immunotherapy. The CheckMate274 trial (NCT02632409) is investigating the use of nivolumab and has so far shown improvements in disease-free survival, with overall survival results pending. The IMvigor010 trial (NCT02450331) investigated the use of atezolizumab and was a negative trial, however retrospective analyses have shown that patients who had circulating tumor DNA (ctDNA) achieved better outcomes when treated with atezolizumab, compared to standard of care. Finally, Dr Bellmunt discusses current ongoing trials into the use of chemotherapy plus radiotherapy plus immunotherapy as a bladder-sparing treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.